vs
Side-by-side financial comparison of CytomX Therapeutics, Inc. (CTMX) and SUNation Energy, Inc. (SUNE). Click either name above to swap in a different company.
SUNation Energy, Inc. is the larger business by last-quarter revenue ($27.2M vs $18.7M, roughly 1.5× CytomX Therapeutics, Inc.). SUNation Energy, Inc. runs the higher net margin — 9.6% vs -0.8%, a 10.4% gap on every dollar of revenue. On growth, SUNation Energy, Inc. posted the faster year-over-year revenue change (77.0% vs -25.7%). Over the past eight quarters, SUNation Energy, Inc.'s revenue compounded faster (43.5% CAGR vs -15.9%).
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
Suncor Energy Inc. is a Canadian integrated energy company based in Calgary, Alberta. It specializes in production of synthetic crude from oil sands. In the 2020 Forbes Global 2000, Suncor Energy was ranked as the 48th-largest public company in the world.
CTMX vs SUNE — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.7M | $27.2M |
| Net Profit | $-154.0K | $2.6M |
| Gross Margin | — | 40.7% |
| Operating Margin | -6.9% | 10.7% |
| Net Margin | -0.8% | 9.6% |
| Revenue YoY | -25.7% | 77.0% |
| Net Profit YoY | 97.6% | 138.2% |
| EPS (diluted) | — | $105.59 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $27.2M | ||
| Q3 25 | — | $19.0M | ||
| Q2 25 | $18.7M | $13.1M | ||
| Q1 25 | $50.9M | $12.6M | ||
| Q4 24 | $38.1M | $15.4M | ||
| Q3 24 | $33.4M | $14.7M | ||
| Q2 24 | $25.1M | $13.5M | ||
| Q1 24 | $41.5M | $13.2M |
| Q4 25 | — | $2.6M | ||
| Q3 25 | — | $-393.0K | ||
| Q2 25 | $-154.0K | $-9.6M | ||
| Q1 25 | $23.5M | $-3.5M | ||
| Q4 24 | $18.9M | $-6.8M | ||
| Q3 24 | $5.7M | $-3.3M | ||
| Q2 24 | $-6.5M | $-6.9M | ||
| Q1 24 | $13.8M | $1.2M |
| Q4 25 | — | 40.7% | ||
| Q3 25 | — | 38.0% | ||
| Q2 25 | — | 37.0% | ||
| Q1 25 | — | 35.1% | ||
| Q4 24 | — | 36.4% | ||
| Q3 24 | — | 35.6% | ||
| Q2 24 | — | 35.4% | ||
| Q1 24 | — | 36.4% |
| Q4 25 | — | 10.7% | ||
| Q3 25 | — | -1.3% | ||
| Q2 25 | -6.9% | -16.6% | ||
| Q1 25 | 44.4% | -17.2% | ||
| Q4 24 | 46.4% | -42.3% | ||
| Q3 24 | 12.3% | -10.9% | ||
| Q2 24 | -33.7% | -15.0% | ||
| Q1 24 | 28.1% | -16.5% |
| Q4 25 | — | 9.6% | ||
| Q3 25 | — | -2.1% | ||
| Q2 25 | -0.8% | -73.5% | ||
| Q1 25 | 46.2% | -27.7% | ||
| Q4 24 | 49.6% | -44.4% | ||
| Q3 24 | 17.2% | -22.4% | ||
| Q2 24 | -26.0% | -51.2% | ||
| Q1 24 | 33.3% | 9.1% |
| Q4 25 | — | $105.59 | ||
| Q3 25 | — | $-0.12 | ||
| Q2 25 | — | $-3.14 | ||
| Q1 25 | — | $-106.71 | ||
| Q4 24 | — | $41676.94 | ||
| Q3 24 | — | $-2350.12 | ||
| Q2 24 | — | $-11022.91 | ||
| Q1 24 | — | $-38414.84 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $49.0M | $7.2M |
| Total DebtLower is stronger | — | $6.6M |
| Stockholders' EquityBook value | $119.9M | $24.3M |
| Total Assets | $175.1M | $48.2M |
| Debt / EquityLower = less leverage | — | 0.27× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $7.2M | ||
| Q3 25 | — | $5.4M | ||
| Q2 25 | $49.0M | $3.2M | ||
| Q1 25 | $47.6M | $1.4M | ||
| Q4 24 | $38.1M | $839.3K | ||
| Q3 24 | $40.6M | $1.1M | ||
| Q2 24 | $43.2M | $1.0M | ||
| Q1 24 | $36.2M | $1.8M |
| Q4 25 | — | $6.6M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $24.3M | ||
| Q3 25 | — | $21.7M | ||
| Q2 25 | $119.9M | $22.1M | ||
| Q1 25 | $25.0M | $14.8M | ||
| Q4 24 | $-456.0K | $8.5M | ||
| Q3 24 | $-23.5M | $13.1M | ||
| Q2 24 | $-31.2M | $-10.9M | ||
| Q1 24 | $-31.7M | $-11.2M |
| Q4 25 | — | $48.2M | ||
| Q3 25 | — | $49.6M | ||
| Q2 25 | $175.1M | $44.1M | ||
| Q1 25 | $98.5M | $44.4M | ||
| Q4 24 | $120.5M | $45.7M | ||
| Q3 24 | $139.0M | $51.0M | ||
| Q2 24 | $159.2M | $52.9M | ||
| Q1 24 | $184.7M | $54.7M |
| Q4 25 | — | 0.27× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.8M | $2.1M |
| Free Cash FlowOCF − Capex | $-15.8M | — |
| FCF MarginFCF / Revenue | -84.6% | — |
| Capex IntensityCapex / Revenue | 0.1% | — |
| Cash ConversionOCF / Net Profit | — | 0.81× |
| TTM Free Cash FlowTrailing 4 quarters | $-77.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $2.1M | ||
| Q3 25 | — | $2.4M | ||
| Q2 25 | $-15.8M | $-130.2K | ||
| Q1 25 | $-21.0M | $-3.4M | ||
| Q4 24 | $-19.9M | $-1.9M | ||
| Q3 24 | $-20.7M | $-968.1K | ||
| Q2 24 | $-19.5M | $-776.4K | ||
| Q1 24 | $-26.0M | $-2.6M |
| Q4 25 | — | — | ||
| Q3 25 | — | $2.4M | ||
| Q2 25 | $-15.8M | — | ||
| Q1 25 | $-21.2M | — | ||
| Q4 24 | $-20.0M | $-1.9M | ||
| Q3 24 | $-20.7M | $-980.3K | ||
| Q2 24 | $-19.6M | $-788.4K | ||
| Q1 24 | $-26.2M | $-2.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | 12.5% | ||
| Q2 25 | -84.6% | — | ||
| Q1 25 | -41.6% | — | ||
| Q4 24 | -52.5% | -12.4% | ||
| Q3 24 | -62.1% | -6.7% | ||
| Q2 24 | -78.2% | -5.8% | ||
| Q1 24 | -63.1% | -20.1% |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | 0.1% | — | ||
| Q1 25 | 0.2% | — | ||
| Q4 24 | 0.2% | 0.0% | ||
| Q3 24 | 0.1% | 0.1% | ||
| Q2 24 | 0.4% | 0.1% | ||
| Q1 24 | 0.3% | 0.0% |
| Q4 25 | — | 0.81× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -0.89× | — | ||
| Q4 24 | -1.05× | — | ||
| Q3 24 | -3.61× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -1.89× | -2.20× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
SUNE
| Transferred At Point In Time | $15.1M | 55% |
| Hawaii Energy Connection | $10.0M | 37% |
| Transferred Over Time | $2.1M | 8% |
